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Centronuclear myopathies (CNMs) are a genetically heterogeneous group of inherited
neuromuscular disorders characterized by clinical features of a congenital myopathy and
abundant central nuclei as the most prominent histopathological feature. The most com-
mon forms of congenital myopathies with central nuclei have been attributed to X-linked
recessive mutations in the MTM1 gene encoding myotubularin (“X-linked myotubular
myopathy”), autosomal-dominant mutations in the DNM2 gene encoding dynamin-2 and
theBIN1 gene encoding amphiphysin-2 (also named bridging integrator-1, BIN1, or SH3P9),
and autosomal-recessive mutations in BIN1, the RYR1 gene encoding the skeletal mus-
cle ryanodine receptor, and the TTN gene encoding titin. Models to study and rescue the
affected cellular pathways are now available in yeast, C. elegans, drosophila, zebrafish,
mouse, and dog. Defects in membrane trafficking have emerged as a key pathogenic
mechanisms, with aberrant T-tubule formation, abnormalities of triadic assembly, and dis-
turbance of the excitation–contraction machinery the main downstream effects studied
to date. Abnormal autophagy has recently been recognized as another important collat-
eral of defective membrane trafficking in different genetic forms of CNM, suggesting an
intriguing link to primary disorders of defective autophagy with overlapping histopatholog-
ical features. The following review will provide an overview of clinical, histopathological,
and genetic aspects of the CNMs in the context of the key pathogenic mechanism, outline
unresolved questions, and indicate promising future lines of enquiry.
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INTRODUCTION
Centronuclear myopathies (CNMs) are a genetically heteroge-
neous group of inherited neuromuscular disorders characterized
by clinical features of a congenital myopathy and abundant central
nuclei as the most prominent histopathological feature [for review,
see Jungbluth et al. (2008)]. CNMs are genetically widely heteroge-
neous and have been attributed to X-linked recessive mutations in
MTM1 encoding myotubularin [“X-linked myotubular myopathy
(XLMTM)”] (Laporte et al., 1996), autosomal-dominant muta-
tions in DNM2 encoding dynamin-2 (Bitoun et al., 2005) and
the BIN1 gene encoding amphiphysin-2 (also named bridging
integrator-1, BIN1, or SH3P9) (Bohm et al., 2014), and autosomal-
recessive mutations in BIN1 (Nicot et al., 2007), RYR1 encoding
the skeletal muscle ryanodine receptor (Wilmshurst et al., 2010),
and TTN encoding titin (Ceyhan-Birsoy et al., 2013).
Whilst histopathological abnormalities other than abundant
central nuclei are not typically observed in association with
MTM1 and BIN1 mutations, the common occurrence of cen-
tral nuclei, marked variability in fiber size and cores with some
of the other genetic backgrounds, in particular recessive RYR1
(Bevilacqua et al., 2011) and TTN mutations (Ceyhan-Birsoy
et al., 2013; Chauveau et al., 2014a), have challenged the concept
of CNM as a “pure” entity (Romero, 2010) and have suggested
a continuum with other congenital myopathies, in particular
the core myopathies [for review, see Jungbluth et al. (2011)]
and congenital fiber type disproportion (CFTD) (Clarke et al.,
2010). The neuromuscular disorder due to dominant mutations
in the CCDC78 gene encoding Coiled-Coil Domain-Containing
78 (Majczenko et al., 2012) is another example of a congenital
myopathy difficult to classify on histopathological grounds due
to the common occurrence of internalized nuclei and cores, con-
taining sarcoplasmic aggregated CCDC78, desmin (DES), actin
(ACTA1), and RYR1.
Models to study and rescue the cellular pathways affected
in various forms of CNM are now available in yeast (Parrish
et al., 2004; Cebollero et al., 2012), C. elegans (Dang et al., 2004;
Zou et al., 2009; Neukomm et al., 2011), drosophila (Velichkova
et al., 2010), zebrafish (Dowling et al., 2009; Gibbs et al., 2013),
mouse (Buj-Bello et al., 2002; Durieux et al., 2010b; Pierson
et al., 2012; Fetalvero et al., 2013; Reifler et al., 2014), and
dog (Beggs et al., 2010; Bohm et al., 2013). Based on obser-
vations in these models, several pathogenic mechanisms have
now been suggested, including abnormalities of triads and cal-
cium handling (Al-Qusairi et al., 2009; Dowling et al., 2009;
Bohm et al., 2014), as well as defects of the neuromuscular
junction (Robb et al., 2011; Dowling et al., 2012), satellite cells
(Lawlor et al., 2012), mitochondria, and the DES cytoskeleton
(Hnia et al., 2011).
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Alterations of the autophagy pathway have recently emerged
as a pathogenic mechanism common to different genetic forms of
CNM (Al-Qusairi et al., 2013; Fetalvero et al., 2013). Autophagy is a
fundamental cellular degradation pathway conserved throughout
evolution with important roles in the removal of defective proteins
and organelles, defense against infections and adaptation to chang-
ing metabolic demands (Mizushima, 2007; Sandri et al., 2013;
Wang and Robbins, 2013). Autophagy is physiologically enhanced
in neurons and muscle, and in conjunction with the ubiquitin–
proteasome pathway, plays a major role in the pathogenesis of
muscle atrophy (Sandri, 2013). The autophagy pathway involves
several tightly regulated steps, evolving from the initial formation
of phagophores to autophagosomes, whose fusion with lysosomes
results in the final structures of degradation, autolysosomes [for
review, see Mizushima (2007)]. The recent implication of defective
autophagy in CNM corresponds to the recognition of its increas-
ing role in a wide range of neuromuscular disorders with both
primary and secondary autophagy defects (Merlini and Nishino,
2014). The observation of histopathological features closely resem-
bling CNM in Vici syndrome (McClelland et al., 2010), a severe
human multisystem disorders due to recessive mutations affecting
the key autophagy regulator epg5 (Cullup et al., 2013), provides
additional support for a link between the CNMs and the autophagy
pathway.
The majority of the defective proteins implicated in the CNMs
to date – myotubularin, dynamin-2, and amphiphysin-2 – are
involved in various aspects of membrane trafficking and remod-
eling relevant to essential cellular processes including endocytosis,
intracellular vesicle trafficking, and autophagy [for review, see
Cowling et al. (2012)], suggesting a pathogenic “master mech-
anism” upstream of the more specific downstream pathogenic
mechanisms outlined above. However, a link between membrane
trafficking and other genes implicated in the CNMs is not imme-
diately obvious, and the communality of clinico-pathological fea-
tures between MTM1, DNM2, and BIN1-related CNM on one
hand and the more recently reported forms due to recessive muta-
tions in RYR1 and TTN on the other hand remains currently
unaccounted for on the molecular level.
The following review will give an overview of the key clini-
cal, histopathological, and genetic aspects of the different forms
of CNM, outline pathogenic mechanisms where already known,
with a particular emphasis on defects in membrane trafficking and
autophagy, and summarize unresolved questions and future lines
of enquiry. Table 1 summarizes the genes and proteins implicated
in the CNMs and outlines their main function(s) where known.
Figure 1 illustrates tentative links between the different pathways
implicated in the CNMs.
MTM1-RELATED CNM (“X-LINKED MYOTUBULAR
MYOPATHY”)
Centronuclear myopathy due to X-linked recessive mutations in
the myotubularin (MTM1) gene (also commonly referred to as
XLMTM) is a rare congenital myopathy that affects approximately
2/100000 male births per year [for review, see Jungbluth et al.
(2008)].
X-linked myotubular myopathy is characterized by a severe
phenotype in males with often antenatal onset, profound
hypotonia, and weakness at birth with associated severe respi-
ratory and bulbar involvement necessitating invasive ventilation
and nasogastric tube feeds. Extraocular muscle involvement is
common. The condition is usually fatal within the first year of
life but a proportion of more mildly affected males may survive
into adolescence or adulthood, sometimes even without requiring
constant ventilatory support. Although profound muscle involve-
ment is the most dramatic and earliest feature of myotubularin
deficiency, long-term survivors show additional organ manifesta-
tions such as hepatic peliosis suggestive of a multisystem disorder
(Herman et al., 1999), indicating that myotubularin does play a
vital role in tissues other than muscle. Moreover, despite muscle
atrophy and weakness, males with XLMTM typically exhibit signs
of macrosomia consistent with an overgrowth syndrome (Leguen-
nec et al., 1988; Joseph et al., 1995), suggesting a differential effect
of myotubularin deficiency on muscle and other growth pathways.
A dilated cardiomyopathy has been reported in two adult brothers
with a mild form of XLMTM (Yu et al., 2003), raising the possi-
bility of a cardiac phenotype in long-term survivors that remains
to be systematically evaluated. Histopathological features in addi-
tion to numerous central nuclei include type 1 predominance and
hypotrophy, a region devoid of myofibrils surrounding the cen-
tral nucleus and necklace fibers (Romero and Bitoun, 2011), but
additional sarcomeric disorganization or overt cores are unusual
in contrast to the DNM2-, RYR1- and TTN -related forms.
More than 300 MTM1 mutations have been identified to date
(Laporte et al., 2000; Herman et al., 2002; Biancalana et al.,
2003; Tsai et al., 2005), distributed throughout the entire coding
sequence and with only few recurrent substitutions. Genotype–
phenotype studies have been limited due to the private nature
of many MTM1 mutations, however, not unexpectedly truncat-
ing mutations usually give rise to the more severe phenotype
whilst non-truncating mutations outside the myotubularin cat-
alytic domain have been associated with milder presentations.
Markedly skewed X-inactivation in manifesting females (Jung-
bluth et al., 2003), as well as complex rearrangements involving
the MTM1 locus have also been recently reported (Trump et al.,
2011; Amburgey et al., 2013).
Myotubularin defines a family of 14 phosphoinositide phos-
phatases in mammals [for review, see Laporte et al. (1998, 2001,
2003), Begley and Dixon (2005), Clague and Lorenzo (2005),
Robinson and Dixon (2006), and Amoasii et al. (2012)], two of
which, MTMR2 and MTMR13, have also been implicated in dif-
ferent forms of Charcot-Marie-Tooth (CMT) disease, CMT4B1
(Berger et al., 2002) and CMT4B2 (Azzedine et al., 2003), respec-
tively. In addition to the catalytic and enzymatically active domain,
myotubularin contains four other domains, including a coiled–
coiled domain involved in homo- and heterodimer formation.
Apart from the recognized interaction with DES, only little is
known about interactions with other proteins in skeletal muscle.
Myotubularin dephosphorylates phosphatidylinositol 3-
phosphate [PI(3)P] and phosphatidylinositol 3,5-phosphate
[PI(3,5)P] [(Blondeau et al., 2000; Taylor et al., 2000;
Tronchere et al., 2004); for review, see Tronchere et al. (2003),
Robinson and Dixon (2006), and Rohde et al. (2009)], second
messengers with a crucial role in membrane trafficking whose
production is under the control of specific phosphatidylinositide
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Table 1 | Genes and proteins implicated in various forms of centronuclear myopathy (CNM).
Gene Inheritance Protein Principal function(s) Main pathogenic effects in muscle
MTM1 XL Myotubularin PI3P regulation
Membrane formation/trafficking
Endocytosis
Endo(lyso)some formation
Abnormal nuclear positioning
Abnormalities of triad positioning and function
Abnormal autophagy
Abnormal cytoskeletal architecture
Abnormal mitochondrial positioning
Autophagosome formation
DNM2 AD Dynamin-2 Membrane formation/trafficking
Vesicle formation and fission
Abnormal nuclear positioning
Abnormalities of triad positioning and function
Abnormal autophagy
Abnormal cytoskeletal architecture
Abnormal mitochondrial positioning
BIN1 AR, AD Amphiphysin-2 Membrane remodeling Abnormalities of nuclear positioning, triad
assembly and function
RYR1 AR Skeletal muscle
ryanodine receptor
Sarcoplasmic reticulum calcium release Abnormal nuclear positioning
Abnormalities of triad assembly and function
Abnormal SR calcium release
TTN AR Titin Elastic link between actin and myosin filaments
Organizer of Z-disk and M-band assembly
Organizer of myosin filament, possibly by regulating
myosin motor domains
Mechanosensor
Signaling scaffold organizing ubiquitin–proteasome
and autophagy–lysosomal protein turnover
Abnormal sarcomere assembly and turnover
Disrupted force transmission
Abnormal myosin force generation
Abnormal transcriptional regulation
MTMR14 AR? Digenic? hJUMPY PI3P regulation
Membrane formation/trafficking
Abnormal nuclear positioning
Abnormal excitation–contraction coupling
Abnormal autophagy
CCDC78 AD Coiled-coil domain-
containing protein 78
Centriole biogenesis? Abnormal nuclear positioning
Core formation?
kinases. In skeletal muscle, the main generator of PI(3)P is the PI3
kinase PIK3C3 (Backer, 2008; Meijer and Klionsky, 2011), a key
regulator of a wide range of cellular processes including autophagy,
in particular formation and maturation of autophagosomes
(Funderburk et al., 2010).
The fundamental role of myotubularin and its orthologs in
PI3P regulation, endocytosis, and endo(lyso)somal function has
been documented in drosophila, C. elegans, zebrafish, mouse,
and higher mammalian models of myotubularin deficiency [for
review, see Cowling et al. (2012)]. Zebrafish morphants following
mtm1 morpholino knockdown show abnormal motor behavior
and reproduce some of the histopathological features also seen in
human XLMTM, associated with increased PI3P levels in muscle
(Dowling et al., 2009). In contrast to human XLMTM, the mtm1
knockout mouse develops muscle weakness and atrophy only in
the postnatal period, suggesting an effect of myotubularin defi-
ciency on muscle maintenance rather than muscle development
(Buj-Bello et al., 2002). Secondary abnormalities of T-tubules, sar-
coplasmic reticulum (SR) and the triads (Al-Qusairi et al., 2009;
Dowling et al., 2009; Beggs et al., 2010; Toussaint et al., 2011)
and, less frequently, abnormalities of intermediate filaments and
mitochondrial dynamics (Hnia et al., 2011) have been reported
as an important common downstream effect of myotubularin
deficiency in zebrafish, mouse, dog, and humans.
Initiation of autophagy, in particular formation of autophago-
somes and autophagosome–lysosome fusion, depends on PI3P
synthesis (Vergne and Deretic, 2010; Cebollero et al., 2012), and
the concerted interaction of autophagy-related (Atg) proteins at
the phagophore assembly site (PAS) (Lamb et al., 2013; Ge et al.,
2014); considering the important role of myotubularin in regu-
lating PI3P levels in muscle, it is not surprising that alterations of
muscle autophagy have now been reported in animal models of
XLMTM: In particular, a marked disturbance of autophagy has
been reported in zebrafish following double knockdown of the
myotubularin family members MTM1 and MTMR14 (Dowling
et al., 2010), the latter also known as Jumpy and implicated in very
rare digenic forms of CNM (Tosch et al., 2006). Mytotubularin
deficiency has also been associated with increased mTORC1 activ-
ity, disconnection between starvation and autophagy induction
(Fetalvero et al., 2013), increased IGF1R/Akt signaling, upreg-
ulation of atrogenes and an increase in autophagy markers in
the mtm1 knockout mouse (Al-Qusairi et al., 2013), indicating
both up- and downstream effects of murine myotubularin defi-
ciency on the autophagy pathway that are potentially amenable
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FIGURE 1 |Tentative links between membrane signaling, sarcomere
activity, and nuclear positioning. T-tubules (T) link the sarcolemma to the
sarcoplasmic reticulum (SR) at the triads by contacts between
dihydropyridine receptors (small orange oval) and ryanodine receptors
(small green oval). Phosphoinositol phosphates (PIP; blue hexagonal
symbols at SR membrane) are turned over by the lipid phosphatase
myotubularin, regulating membrane dynamics, and PIP-dependent
downstream signaling. This affects multiple pathways, including autophagy.
Altered membrane remodeling and microtubular transport will converge on
these pathways. Defects affecting Titin’s scaffolding role concerning
multiple components of the protein quality control machinery impinge on
contractile function, sarcomere turnover and possibly sarcomere-nuclear
links. Nuclei and sarcomeres are joined by peripheral cytoskeletal
networks, including desmin intermediate filaments and nesprin via
“transmembrane actin-associated nuclear links” (Luxton et al., 2011). 1,
Mutations affecting lipid phosphatase activity of myotubularin (MTM1 and
MTMR14); 2, mutations in components of the membrane remodeling
machinery (BIN1); 3, defects in vesicular traffic or microtubule dynamics
(DNM2); 4, mutations in the endosomal–autophagosomal–lysosomal
pathway (EPG5); 5, defective calcium homeostasis and
excitation–contraction coupling (RYR1); 6, defective sarcomeric
maintenance and protein quality control (TTN); 7, disrupted nuclear
cytoskeleton links, abnormal nuclear positioning and possibly impaired triad
function via impaired microtubule/centriole function (CCDC78).
to mTOR inhibition with Rapamycin (Fetalvero et al., 2013)
and adeno-associated virus (AAV)-mediated delivery of func-
tional myotubularin (Al-Qusairi et al., 2013). Interestingly, a
recent study reporting a muscle-specific conditional knockout
of PIK3C3, the phosphatidylinositide 3-kinase critical for PI3P
levels in muscle, indicates marked autophagolysosomal abnormal-
ities with histopathological features more suggestive of a muscular
dystrophy rather than CNM (Reifler et al., 2014). These observa-
tions suggest the autophagy pathway and its upstream regulators
as potential therapeutic targets in CNM and, possibly, other forms
of neuromuscular disorders.
DNM2 -RELATED CNM
Dominantly inherited DNM2-related CNM is usually much
milder than X-linked and recessive forms of CNM although more
severe presentations have been reported [for review, see Jungbluth
et al. (2008)]. Onset is typically in adolescence or early adulthood,
featuring predominant proximal weakness with additional distal
involvement particularly in the lower limbs, ptosis with exter-
nal ophthalmoplegia, and a stable or slowly progressive course.
Exertional myalgia may be the presenting feature before the evo-
lution of overt weakness and muscle hypertrophy, occasionally
localized, has been observed (Liewluck et al., 2010). Specific dom-
inant intermediate (CMTDIB) and axonal forms of CMT disease
(CMT2), respectively, are allelic conditions (Zuchner et al., 2005;
Fabrizi et al., 2007). In addition to myopathic changes, EMG and
nerve conduction studies may show mild signs of axonal peripheral
nerve involvement also in DNM2-related CNM patients (Fischer
et al., 2006; Echaniz-Laguna et al., 2007), suggesting a clinical
continuum between myopathic and neuropathic manifestations
of DNM2 mutations. Other DNM2-mutated patients may fea-
ture additional neutropenia (Liewluck et al., 2010) or cataracts
(Jungbluth et al., 2010), suggesting a role of dynamin-2 in tissues
other than muscle, as well as clinical overlap with multisystem
disorders due to primary autophagy defects such as EPG5-related
Vici syndrome (Cullup et al., 2013), where cataracts and hemato-
logical abnormalities are common. Homozygosity for the DNM2
Phe379Val missense mutation has been recently associated with a
congenital lethal syndrome in humans (Koutsopoulos et al., 2013).
Histopathological features in addition to centralized nuclei may
include type 1 predominance, typical sarcoplasmic radial strands
surrounding the central nuclei, increases in connective tissues
and cores (Fischer et al., 2006; Schessl et al., 2007; Jeub et al.,
2008; Hanisch et al., 2011; Bohm et al., 2012a; Catteruccia et al.,
2013).
The DNM2 gene is one of three members of the dynamin fam-
ily (Praefcke and McMahon, 2004) and ubiquitously expressed, in
contrast to DNM1 that is mainly expressed in the brain, and DNM3
expressed in brain and testes. DNM2 encodes a large GTPase pro-
tein organized in five functional domains, an N-terminal GTPase
domain, a middle domain (MD), a pleckstrin homology (PH)
domain, a GTPase effector domain, and a C-terminal proline
rich domain (PRD) (McNiven, 2005). Through its PH and PRD
domains, dynamin-2 binds to phosphoinositides and SH3 domain
proteins such as amphiphysin, respectively. Dominant mutations
affecting the dynamin-2 MD have been associated with a mild
phenotype of CNM (Bitoun et al., 2005), whilst more severe
presentations with neonatal onset have been attributed to het-
erozygous de novo dominant mutations affecting the PH domain
(Bitoun et al., 2007; Jungbluth et al., 2010). The dynamin-2 PH
domain is also predominantly affected by DNM2 mutations caus-
ing primary neuropathic phenotypes. A recurrent DNM2 muta-
tion (c.1393C>T; p.Arg465Trp) has been identified in a number
of unrelated autosomal-dominant pedigrees with a mild form
of CNM.
Dynamins are involved in membrane fission, and the role of
various isoforms including dynamin-2 in clathrin-dependent and
independent endocytosis, vesicle formation and processing (Jones
et al., 1998; Praefcke and McMahon, 2004; Durieux et al., 2010a)
has been documented in various models of dynamin deficiency.
Additional roles have been proposed in the microtubule network,
actin cytoskeleton assembly (Gu et al., 2010), and centrosome
cohesion (Thompson et al., 2004), the latter of potential relevance
for the nuclear abnormalities observed in DNM2-related CNM.
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Murine models of the common human DNM2 R465W domi-
nant CNM mutation do replicate aspects of the human pheno-
type, and not unexpected considering the close links between
endocytic and autophagic pathways, show variable abnormali-
ties of autophagy: Durieux et al. (2010b, 2012) demonstrated a
slowly progressive myopathy with upregulation of genes involved
in ubiquitin–proteosome (UPS) and autophagy pathways in a
heterozygous knock-in mouse model of the common CMT-
associated heterozygous DNM2 mutation R465W. Mice homozy-
gous for the R465W mutation showed a severe phenotype similar
to what has been observed in other mouse models of dysregulated
autophagy (Durieux et al., 2012), characterized by increased glyco-
gen storage, hepatomegaly, hypoglycemia, and early lethality. The
same mice showed microscopic evidence of delayed autophago-
some maturation and of reduced autophagic flux on in vitro
studies. Another mouse model generated by intramuscular AAV
injection of mutant R465W–DNM2 generated histopathological
abnormalities and T-tubule defects similar to those observed in
humans and animal models of other forms of CNM, suggest-
ing a muscle maintenance defect as the principal abnormality
also in DNM2-related CNM. An intriguing and potentially ther-
apeutically exploitable link between DNM2- and MTM1-related
pathways has been recently indicated by demonstrating rescue of
the XLMTM phenotype through dynamin-2 reduction in mice
(Cowling et al., 2014).
BIN1-RELATED CNM
Autosomal-recessive BIN1-related CNM has only been reported
in a small number of families associated with a mild to moder-
ate phenotype characterized by early-childhood onset, extraocular
muscle involvement and slowly progressive muscle weakness, and
atrophy (Nicot et al., 2007; Claeys et al., 2010). However, more
severe, early-onset lethal (Nicot et al., 2007) and rapidly progres-
sive presentations due to homozygous BIN1 mutations affecting
splicing have been reported (Bohm et al., 2010, 2013). Dominant
inheritance of BIN1 mutations has also been recently recognized
(Bohm et al., 2014). In addition to central nuclei, type 1 fiber-type
predominance may be an additional feature, but sarcomeric dis-
organization and core-like areas are uncommon [for review, see
Jungbluth et al. (2008)].
BIN1 encodes amphiphysin-2, a protein belonging to the BAR
(Bin/Amphiphysin/Rvs) domain-containing family of proteins
(Peter et al., 2004) involved in various key cellular processes
including membrane recycling and endocyotosis [for review, see
Prokic et al. (2014)]. Corresponding to other proteins implicated
in the CNMs, BIN1 also contains a phosphoinositide-binding
domain and is involved in T-tubule formation. Mutations affect-
ing the BIN1 BAR domain impair membrane tubulation and result
in structural abnormalities (Wu et al., 2014). BIN1 is ubiqui-
tously expressed but subject to tissue-specific alternative splicing,
whereas amphiphysin 1, the other member of the amphiphysin
family, is mainly expressed in brain. BIN1 downregulation has been
associated with cancer progression and cardiac disease, whereas
BIN1 overexpression has been linked to an increased risk for
late-onset Alzheimer disease [for review, see Prokic et al. (2014)].
The essential role of amphiphysins and their orthologs in
endocytosis, membrane remodeling and recycling has been
documented in drosophila and C. elegans models of amphiphysin
deficiency [for review, see Cowling et al. (2012)]. A recent Bin1-
deficient zebrafish model of BIN1-related CNM reproduces the
histopathological features of the human phenotype, and indicates
abnormal calcium release resulting from aberrant triad formation
as an important pathogenic mechanism downstream of the prin-
cipal membrane remodeling abnormality (Smith et al., 2014). The
T-tubule and triadic abnormalities observed in the Bin1-deficient
zebrafish model are similar to those observed in MTM1- and
DNM2-related CNM (Toussaint et al., 2011), indicating a shared
pathogenic mechanism due to implication of the defective pro-
teins in the same pathway. BIN1-deficient mice show early lethality
(Muller et al., 2003), but murine skeletal muscle has not yet been
thoroughly analyzed. A recent mouse model of Bin1 depletion in
the heart shows abnormalities of T-tubule folding resulting in free
diffusion of local extracellular calcium and potassium ions, pro-
longed action-potential duration and increased susceptibility to
ventricular arrhythmias (Hong et al., 2014).
BIN1 deficiency has not yet been associated with defects in the
autophagy pathway, however, it is of note that structurally related
BAR domain-containing proteins such as SH3P2 translocate to the
PAS following autophagy induction and appear to play a role in
autophagosome formation (Zhuang et al., 2013).
RYR1-RELATED CNM
Recessive mutations in RYR1 are another cause of congenital
myopathies with central nuclei (Wilmshurst et al., 2010). RYR1
mutations are one of the most common causes of inherited
neuromuscular disorders, ranging from the malignant hyperther-
mia susceptibility (MHS) trait without any associated weakness
to various congenital myopathies, including mainly dominantly
inherited Central Core Disease (CCD) as well as mainly reces-
sively inherited Multi-minicore Disease (MmD) [for review, see
Jungbluth et al. (2011)], CFTD (Clarke et al., 2010), and CNM
(Wilmshurst et al.,2010). The genetics of RYR1-related myopathies
are not infrequently complex, occasionally with two clearly path-
ogenic RYR1 mutations occurring on the same allele or run-
ning independently in the same family, possibly accounting for
the wide phenotypical variability and variable penetrance (Klein
et al., 2012). There is substantial clinical and pathological overlap
between MmD, CFTD, and CNM due to recessive RYR1 mutations,
and it appears appropriate to view these conditions as part of a
recessive RYR1-related continuum rather than completely distinct
entities.
Clinically, RYR1-related CNM is of intermediate severity com-
pared to other genetic forms, with facial weakness, external oph-
thalmoplegia, predominantly proximal muscle involvement but
less pronounced bulbar or respiratory impairment (Wilmshurst
et al., 2010). There is however, a more severe end of the spec-
trum, with some profoundly affected males showing clinical
presentations indistinguishable from the XLMTM phenotype.
Patients with RYR1-related CNM show a marked tendency to
improve over time, even following an initially severe presentation,
a feature also in other recessive RYR1-related myopathies (Bohm
et al., 2012b) that remains currently unexplained.
On the pathological level, central and multiple internalized
nuclei are often the principal histopathological feature when
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muscle biopsy is performed early in life (Jungbluth et al., 2007), but
other histopathological features typically associated with recessive
RYR1-related myopathies – marked type 1 predominance or uni-
formity, fiber type disproportion and cores – may evolve over time
(Bevilacqua et al., 2011).
In contrast to dominantly inherited MHS and CCD where most
features can be explained by abnormal calcium release from the
mutant RyR1 channel [for review, see Treves et al. (2005)], the
pathogenesis of recessive RYR1-related myopathies is currently
only partly understood and probably more complex. Recessive
RYR1 genotypes, often featuring compound heterozygosity for
RYR1 missense and truncating mutations, result in reduced expres-
sion of the RyR1 protein and secondary reduction of the DHPR
receptor, its principal ligand (Wilmshurst et al., 2010; Bevilac-
qua et al., 2011; Zhou et al., 2013). Additional upregulation of
the IP3R receptor may be found in some cases, an observation
currently of uncertain significance (Zhou et al., 2013). Whilst
the concomitant reduction of RyR1 and DHPR and the resulting
excitation–contraction (EC) coupling defect are likely to explain
the weakness, muscle atrophy as well as histopathological fea-
tures of fiber-type disproportion and centralized nuclei are not
readily explained by alterations of calcium release in recessive
RYR1-related myopathies.
In contrast to other genetic forms of CNM, defects in mem-
brane trafficking and autophagy have not been implicated in
recessive RYR1-related CNM. However, it is of note that marked
autophagy abnormalities have been observed in mice follow-
ing induced reduction of the DHPR receptor (Pietri-Rouxel
et al., 2010), a secondary feature also in recessive RYR1-related
myopathies. In addition, the recent implication of annexin-1
and annexin-5, members of the annexin family of proteins that
bind to phospholipid membranes in a calcium-dependent man-
ner, in autophagosome maturation (Ghislat and Knecht, 2012)
suggests a potential link between disturbed calcium homeostasis
and autophagy regulation that may warrant further investigation.
Effect of altered calcium release on autophagic pathways have been
previously considered but with conflicting conclusions (East and
Campanella, 2013).
TTN -RELATED CNM
Recessive mutations in TTN encoding the giant sarcomeric
ruler protein titin have recently been identified by next gener-
ation sequencing in five individuals selected from a cohort of
29 unrelated and genetically unresolved patients with a clinico-
pathological diagnosis of CNM (Ceyhan-Birsoy et al., 2013). TTN
mutations have recently also been indicated as one of the most
common identifiable genetic causes of dilated cardiomyopathy
(Herman et al., 2012), and have been implicated in a wide range
of neuromuscular disorders, including late-onset tibial muscu-
lar dystrophy, limb girdle muscular dystrophy type 2J (LGMD2J),
hereditary myopathy with early respiratory failure (HMERF),
and early-onset myopathy with fatal cardiomyopathy [reviewed
recently in Chauveau et al. (2014b)]. Although the functional
relevance and clear genotype–phenotype correlations have been
established for many unequivocally pathogenic TTN mutations,
it is also important to bear in mind that truncating TTN vari-
ants are exceedingly common [over 6000 in the December 2014
release of the 1000 genomes database, and ca. 3% of controls
reported in Herman et al. (2012)] and that pathogenicity is not
always immediately evident even if those variants are truncating.
This might be due to tissue-specific and developmentally regu-
lated exon usage, especially in the extensively differentially spliced
I-band region of titin (Bang et al., 2001), making some truncating
variants penetrant in only a small subset of titin isoforms. But also,
truncating mutations near the C-terminus appear, on the whole, to
be recessive without an adult phenotype (Carmignac et al., 2007;
Ceyhan-Birsoy et al., 2013; Chauveau et al., 2014a). The reasons
for the recessive inheritance of truncating variants in constitutively
expressed exons remains to be understood.
Clinical features of the five patients with TTN -related CNM
in the study by Ceyhan-Birsoy et al. (2013) were characterized
by early-childhood onset, generalized weakness, and respiratory
impairment, but without evidence of cardiac involvement at the
time of the last follow-up in childhood or late adolescence (5–
19 years). In contrast to other genetic forms of CNM, extraocular
muscles were spared and in one case CK levels were increased
>1000 IU/l. Histopathological features included increases in con-
nective tissue, fiber type disproportion, and type 1 predominance
and hypotrophy. In contrast to MTM1-related CNM, but cor-
responding to findings in the RYR1-related form, central and
internalized nuclei were typically multiple rather than single. Sim-
ilar observations were made in the seminal paper on the recessive
truncating TTN -linked early-onset Salih myopathy (Carmignac
et al., 2007) and in four families with compound heterozygous
TTN variants in Autosomal-Recessive Multi-minicore Disease
with Heart Disease (AR MmD-HD) (Chauveau et al., 2014a).
Patients with AR MmD-HD show marked centronucleation with
additional morphological changes, notably the formation of pro-
tein aggregates and Z-disk streaming that show ultrastructural
similarities to those found in myofibrillar myopathy. Patients also
display various cardiac phenotypes, from left-ventricular non-
compaction to septal defects (ASD and VSD) and dilated car-
diomyopathy, in some instances requiring transplantation (Chau-
veau et al., 2014a). Additional findings of core-like areas on
oxidative stain and myofibrillar disruption on EM, in partic-
ular Z-disk streaming and sarcomere disruption, suggest that
TTN -related CNM and AR MmD-HD may be part of a TTN -
related histopathological spectrum rather than a pure entity, again
corresponding to observations in the RYR1-related form.
The pathogenesis of TTN-related CNM and in particular its
association with pathways affected in other forms of CNM, if any,
remains currently uncertain. Most mutations identified in TTN -
related CNM give rise to significant C-terminal truncations, with
or without the expression of disruptive missense variants, result-
ing in secondary reduction of interacting proteins such as nebulin
and calpain-3 that may contribute to the phenotype. Calpain-3 is
required for the normal recruitment of RyR1 receptors to the triad,
a function that, if disturbed, may give rise to similar abnormalities
of triad assembly and EC coupling as seen in other genetic forms of
CNM. A common feature of TTN -linked AR MmD-HD and CNM
is, however, the disruption of titin M-band linked interactions; of
these, three are possibly mechanistically related to pathways linked
to the “classical” CNM variants. Firstly, M-band titin links the
sarcomere to the SR via its interactions with the giant protein
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obscurin (Bagnato et al., 2003; Kontrogianni-Konstantopoulos
et al., 2003; Fukuzawa et al., 2008) and thus contributes to the
organized integration of the EC-coupling machinery of T-tubules,
junctional SR, and sarcomeres. Intriguingly, obscurin knockout
mice also develop a myopathic phenotype with centralized nuclei
and disordered SR (Lange et al., 2009). Secondly, the M-band asso-
ciated kinase domain of titin is linked to the control of protein
turnover via the autophagy cargo adaptors Nbr1 and SQSTM1
[reviewed in Gautel (2011)]. Lastly, mutations in the C-terminus
of titin are linked to secondary calpain-3 deficiency also in the
case of adult titinopathies (Udd, 2012), likely due to the abro-
gation of a calpain-3 binding site near the C-terminus of titin
(Charton et al., 2010). While the connections between titin muta-
tions, protein turnover, and abnormal nuclear positioning in
titin-associated CNM-like myopathies are currently unclear, accu-
mulating evidence suggests that protein turnover via autophagy
and calpain-mediated turnover converge on M-band titin and that
these connections are concerted with physical links to the SR and
triad systems. If such links exist, it seems plausible that the abla-
tion or functional disruption of titin-linked autophagy functions
in M-band titinopathies (Chauveau et al., 2014a) result in partial
phenotypic overlap with membrane-associated components of the
autophagy machinery.
RARE CONGENITAL MYOPATHIES WITH CENTRAL NUCLEI
Congenital myopathies with features of CNM with or without
additional histopathological abnormalities due to uncommon
genetic backgrounds have been observed in isolated families.
Tosch and colleagues reported single heterozygous missense
variants in hJUMPY (also known as MTMR14, a member of the
myotubularin family) in two sporadic cases with features of CNM
and uncertain inheritance (Tosch et al., 2006). Although both
variants were demonstrated to reduce the enzymatic activity of
hJUMPY, identification of an additional DNM2 mutation in one
patient suggests that a second mutation may be required for full
manifestation of clinical features; this is also in keeping with the
observation of a more severe phenotype in the MTM1–MTMR14
zebrafish double knockout compared to knockout of each single
gene (Dowling et al., 2010).
Autosomal-dominant mutations in CCDC78 have also recently
been identified in a single family characterized by core-like
areas and increased internalized nuclei (Majczenko et al., 2012);
CCDC78 encodes a skeletal muscle protein enriched in the
perinuclear region and at the sarcolemma and possibly triad
(Majczenko et al., 2012), suggesting a possible link with a path-
ogenic mechanism, abnormal triad assembly, and resulting dis-
turbance of EC coupling, common to other forms of CNM.
CCDC78 plays a key role in centriole biogenesis (Klos Dehring
et al., 2013); the impaired function in CNM4 and the link to
potential triad malfunction or abnormal nuclear positioning via
impaired microtubule function is currently elusive.
CONCLUSION AND OUTLOOK
Recent years have seen substantial advances in our understanding
of the CNMs, in particular those due to mutations in MTM1,
DNM2, and BIN1, encoding proteins intricately linked in var-
ious aspects of phosphoinositide metabolism and membrane
trafficking, with aberrant T-tubule formation, abnormalities of
triad assembly and disturbance of the EC machinery as the
most important downstream effects studied to date. Abnor-
mal autophagy has recently been recognized as another impor-
tant pathogenic mechanism in different genetic forms of CNM,
suggesting an intriguing link to primary disorders of defec-
tive autophagy with overlapping histopathological features. These
findings have illustrated the role of defective pathways common to
several genetic forms of CNM that may be potentially amenable to
therapeutic intervention. It remains currently uncertain if the pro-
teins encoded by genes more recently implicated in the CNMs, in
particular RYR1 and TTN, are involved with the same pathways or
linked with altogether different mechanisms. The functional links
between the genetic mechanisms implicated in CNM are tenta-
tive at the moment, and it has to be seen whether all myopathies
clinically classified as CNM indeed join into a common pathome-
chanistic pathway. Although the mechanisms outlined above may
at least partially explain the muscle weakness and atrophy observed
in different forms of CNM, other aspects such as the consistent
abnormality of nuclear positioning remain currently unaccounted
for. The molecular machinery involved in nuclear positioning is
currently only partially understood [for review, see Osorio and
Gomes (2014)], but emerging evidence suggests that normal posi-
tioning of the nucleus is a prerequisite for its normal function-
ing (Metzger et al., 2012). Recent work has already suggested a
link between N-WASP and BIN1-related nuclear positioning and
triad organization (Falcone et al., 2014). Further investigation of
the CNMs as a paradigm of disorders with nuclear positioning
as the most prominent pathological hallmark will advance our
understanding of the intricate interaction between the nucleus,
microtubules and the actomyosin cytoskeleton (Luxton et al., 2011;
Cadot et al., 2012), and delineate the importance of the interplay
of these structures for cellular function in health and disease.
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